Modified Mammalian Cells for Reduced Purification Burden
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant proteins in mammalian cells face challenges such as reduced cell viability, productivity, and increased costs due to the expression of endogenous proteins that are not essential for growth or survival, which can co-purify with the product of interest, leading to purification difficulties and decreased product quality.
Innovation Solution
Modified mammalian cells are engineered to reduce or eliminate the expression of specific endogenous proteins like BAX, BAK, ICAM-1, and others that are not essential for cell growth or survival, thereby improving cell culture performance and product quality by minimizing the burden on purification processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If endogenous proteins are expressed in mammalian cells, then cell growth and survival are maintained, but purification burden increases and product quality decreases
Solution Approach 1:
The patent applies the extraction principle by removing specific endogenous proteins (BAX, BAK, ICAM-1, and other non-essential proteins) from the mammalian cell line through genetic modification. This extraction of harmful components directly reduces purification burden and improves product quality without compromising cell viability, as these proteins are not essential for cell growth.
Solution Approach 2:
The patent changes the expression parameters of endogenous proteins by using CRISPR/Cas9 gene editing to knock out specific genes. This parameter change (from expressed to non-expressed) directly addresses the contradiction by eliminating proteins that burden purification processes while maintaining cell growth through preservation of essential proteins.
2Productivity
If endogenous proteins are expressed in mammalian cells, then cell survival is maintained, but additional purification steps are required
Solution Approach 1:
By extracting and eliminating non-essential endogenous proteins through genetic knockouts, the patent reduces the number of purification steps required. This directly increases production efficiency by shortening the purification timeline while maintaining cell survival through preservation of essential proteins.
Solution Approach 2:
The patent applies preliminary action by pre-modifying the cell line to eliminate problematic proteins before the purification process begins. This proactive genetic modification prevents the need for additional purification steps, thereby saving time and improving overall productivity.
3Duration of action of stationary object
If endogenous proteins are expressed in mammalian cells, then cell growth is maintained, but product shelf-life decreases
Solution Approach 1:
The patent extracts and eliminates host cell proteins that act as degradation enzymes or promote particle formation. By removing these harmful substances, the product shelf-life is extended while maintaining cell growth through preservation of essential proteins.
Solution Approach 2:
The patent changes the quantity parameter of host cell proteins by reducing their content through genetic knockout. This parameter change directly improves product shelf-life by eliminating proteins that would otherwise degrade the product over time.
4Reliability
If endogenous proteins are expressed in mammalian cells, then cell viability is maintained, but purification costs increase
Solution Approach 1:
The patent extracts and eliminates specific endogenous proteins that increase purification costs. By removing these non-essential proteins through genetic modification, manufacturing costs are reduced while cell viability is maintained through preservation of essential proteins.
Data Source
AI summary
The present disclosure relates to mammalian cells (e.g., Chinese Hamster Ovary (CHO) cells) that are modified to reduce or eliminate the expression of certain mammalian cell endogenous products (e.g., host cell proteins and virus-like particles), and methods of using such cells in the production of a recombinant product of interest, e.g., a recombinant protein, a recombinant viral particle, or a recombinant viral vector. These modifications were specifically chosen to generate engineered mammalian host cells with desired traits in several key areas, including improved cell culture performance (e.g., higher viability and product titers), improved product quality (e.g., more consistent and favorable glycosylation; more stable drug product), and decreased burden on purification for removing problematic or undesired endogenous host cell products (e.g., hydrolytic host cell proteins and virus-like particles) during biomanufacturing.